Download PDF
Pneumologie 2015; 69(03): 135-143
DOI: 10.1055/s-0034-1391435
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Riociguat: Stimulation der löslichen Guanylatzyklase

Neuer Wirkmechanismus zur Behandlung der pulmonal-arteriellen und der nicht operablen chronisch thromboembolischen pulmonalen HypertonieRiociguat: Stimulator of Soluble Guanylate-cyclaseNew Mode of Action for the Treatment of Pulmonary Arterial and Non Operable Chronic Thromboembolic Pulmonary Hypertension
H. H. Leuchte
1   Innere Medizin II, KH Neuwittelsbach, Akademisches Lehrkrankenhaus LMU, München
,
J. Behr
2   Medizinische Klinik und Polklinik V, Klinikum der Universität München und Asklepios Fachkliniken München-Gauting, Comprehensive Pneumology Center, Mitglied des Deutschen Zentrums für Lungenforschung
,
R. Ewert
3   Bereich Pneumologie/Infektiologie und Weaningzentrum Klinik und Poliklinik für Innere Medizin B Universitätsmedizin Greifswald
,
H. A. Ghofrani
4   Medizinische Klinik II, Universitätsklinikum Gießen Marburg, Deutsches Zentrum für Lungenforschung. Kerckhoff Klinik Bad Nauheim
,
E. Grünig
5   Zentrum Pulmonale Hypertonie der Thoraxklinik Heidelberg am Universitätsklinikum Heidelberg. Mitglied Deutsches Zentrum für Lungenforschung
,
M. Halank
6   Medizinische Klinik und Poliklinik I; Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden
,
M. Held
7   Innere Medizin. Missionsärztliche Klinik Würzburg
,
H. Klose
8   Sektion Pneumologie Onkologisches Zentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg
,
S. Rosenkranz
9   Herzzentrum der Uniklinik Köln
,
R. T. Schermuly
10   Pulmonale Pharmakotherapie Justus Liebig Universität Gießen
,
H. Wilkens
11   Innere Medizin V – Pneumologie, Allergologie, Beatmungs- und Umweltmedizin Universitätsklinikum des Saarlandes, Homburg Saar
,
M. M. Hoeper
12   Klinik für Pneumologie, Medizinische Hochschule Hannover und Deutsches Zentrum für Lungenforschung (DZL)
› Author Affiliations
Further Information

Publication History

eingereicht 26 May 2014

akzeptiert nach Revision 30 June 2014

Publication Date:
06 March 2015 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

Riociguat ist der erste klinisch verfügbare Vertreter der Stimulatoren der löslichen Guanylatzyklase (sGC), einer neuartigen Substanzgruppe. Die primäre Zulassungsindikation erhielt Riociguat für die pulmonal-arterielle Hypertonie (PAH) und für die Behandlung der nicht operablen bzw. postoperativ wiederkehrenden/persistierenden chronisch thomboembolischen pulmonalen Hypertonie (CTEPH). Darüber hinaus besteht ein Studienprogramm in weiteren Indikationsgebieten.

Der nachfolgende Artikel beschreibt den Wirkmechanismus und die bisher verfügbaren klinischen Daten von Riociguat. Zudem ziehen die Autoren aus den vorliegenden Daten, der Zulassungs- und der Kostensituation ein Fazit für die Integration von Riociguat in den bisherigen Therapiealgorithmus der PAH und CTEPH.

 

  • Literatur

  • 1 Hoeper MM, Bogaard HJ, Condliffe R et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D42-50
    CrossrefPubMedGoogle Scholar
  • 2 Simonneau G, Gatzoulis MA, Adatia I et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D34-41
    CrossrefPubMedGoogle Scholar
  • 3 DʼAlonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349
    CrossrefPubMedGoogle Scholar
  • 4 Vachiery JL, Adir Y, Barbera JA et al. Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 2013; 62: D100-108
    CrossrefPubMedGoogle Scholar
  • 5 Wagenvoort CA. Pathology of pulmonary thromboembolism. Chest 1995; 107: 10S-17S
    CrossrefPubMedGoogle Scholar
  • 6 Wilkens H, Lang I, Behr J et al. Chronic thromboembolic pulmonary hypertension (CTEPH): updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 2011; 154 (Suppl. 01) 54-60
    CrossrefPubMedGoogle Scholar
  • 7 Hoeper MM, Markevych I, Spiekerkoetter E et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005; 26: 858-863
    CrossrefPubMedGoogle Scholar
  • 8 Hoeper MM, Huscher D, Ghofrani HA et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 2013; 168: 871-880
    CrossrefPubMedGoogle Scholar
  • 9 Arcangeli C, Squillantini G, Santoro G et al. [Association of pulmonary and portal hypertension]. Minerva Cardioangiol 1996; 44: 343-352
    PubMedGoogle Scholar
  • 10 Held M, Walthelm J, Baron S et al. Functional impact of pulmonary hypertension due to hypoventilation and changes under noninvasive ventilation. Eur Respir J 2014; 43: 156-165
    CrossrefPubMedGoogle Scholar
  • 11 Friebe A, Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 2003; 93: 96-105
    CrossrefPubMedGoogle Scholar
  • 12 Follmann M, Griebenow N, Hahn MG et al. The chemistry and biology of soluble guanylate cyclase stimulators and activators. Angewandte Chemie 2013; 52: 9442-9462
    CrossrefPubMedGoogle Scholar
  • 13 Ghofrani HA, Pepke-Zaba J, Barbera JA et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 68S-72S
    CrossrefPubMedGoogle Scholar
  • 14 Takimoto E. Cyclic GMP-dependent signaling in cardiac myocytes. Circ J 2012; 76: 1819-1825
    CrossrefPubMedGoogle Scholar
  • 15 Girgis RE, Champion HC, Diette GB et al. Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. Am J Respir Crit Care Med 2005; 172: 352-357
    CrossrefPubMedGoogle Scholar
  • 16 Malerba M, Radaeli A, Ragnoli B et al. Exhaled nitric oxide levels in systemic sclerosis with and without pulmonary involvement. Chest 2007; 132: 575-580
    CrossrefPubMedGoogle Scholar
  • 17 Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214-221
    CrossrefPubMedGoogle Scholar
  • 18 Kielstein JT, Bode-Boger SM, Hesse G et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2005; 25: 1414-1418
    CrossrefPubMedGoogle Scholar
  • 19 Pullamsetti S, Kiss L, Ghofrani HA et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J 2005; 19: 1175-1177
    PubMedGoogle Scholar
  • 20 Skoro-Sajer N, Mittermayer F, Panzenboeck A et al. Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2007; 176: 1154-1160
    CrossrefPubMedGoogle Scholar
  • 21 Xu W, Kaneko FT, Zheng S et al. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 2004; 18: 1746-1748
    PubMedGoogle Scholar
  • 22 Bowers R, Cool C, Murphy RC et al. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med 2004; 169: 764-769
    CrossrefPubMedGoogle Scholar
  • 23 Cracowski JL, Degano B, Chabot F et al. Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension. Chest 2012; 142: 869-876
    CrossrefPubMedGoogle Scholar
  • 24 Developing new guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009; 30: 2416-2418
    PubMedGoogle Scholar
  • 25 Black SM, Sanchez LS, Mata-Greenwood E et al. sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001; 281: L1051-1057
    PubMedGoogle Scholar
  • 26 Maclean MR, Johnston ED, McCulloch KM et al. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther 1997; 283: 619-624
    PubMedGoogle Scholar
  • 27 Farrow KN, Lee KJ, Perez M et al. Brief hyperoxia increases mitochondrial oxidation and increases phosphodiesterase 5 activity in fetal pulmonary artery smooth muscle cells. Antioxid Redox Signal 2012; 17: 460-470
    CrossrefPubMedGoogle Scholar
  • 28 Farrow KN, Wedgwood S, Lee KJ et al. Mitochondrial oxidant stress increases PDE5 activity in persistent pulmonary hypertension of the newborn. Respir Physiol Neurobiol 2010;
    PubMedGoogle Scholar
  • 29 Galie N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157
    CrossrefPubMedGoogle Scholar
  • 30 Galie N, Brundage BH, Ghofrani HA et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903
    CrossrefPubMedGoogle Scholar
  • 31 Schermuly RT, Stasch JP, Pullamsetti SS et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008; 32: 881-891
    CrossrefPubMedGoogle Scholar
  • 32 Stasch JP, Evgenov OV. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol 2013; 218: 279-313
    PubMedGoogle Scholar
  • 33 Frey R, Muck W, Unger S et al. Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers. J Clin Pharmacol 2008; 48: 1400-1410
    CrossrefPubMedGoogle Scholar
  • 34 Frey R, Muck W, Unger S et al. Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. J Clin Pharmacol 2008; 48: 926-934
    CrossrefPubMedGoogle Scholar
  • 35 Grimminger F, Weimann G, Frey R et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009; 33: 785-792
    CrossrefPubMedGoogle Scholar
  • 36 Ghofrani HA, Voswinckel R, Gall H et al. Riociguat for pulmonary hypertension. Future Cardiol 2010; 6: 155-166
    CrossrefPubMedGoogle Scholar
  • 37 Ghofrani HA, Galie N, Grimminger F et al. Riociguat for the treatment of pulmonary arterial hypertension. NEJM 2013; 369: 330-340
    CrossrefPubMedGoogle Scholar
  • 38 Galie N, Neusser D, Muller K et al. A Placebo-Controlled, Double-Blind Phase II Interaction Study To Evaluate Blood Pressure Following Addition Of Riociguat To Patients With Symptomatic Pulmonary Arterial Hypertension (pah) Receiving Sildenafil (PATENT plus). ATS: Am J Respir Crit Care Medicine 2013; p. A 3530
    PubMedGoogle Scholar
  • 39 Ghofrani HA, DʼArmini AM, Grimminger F et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. NEJM 2013; 369: 319-329
    CrossrefPubMedGoogle Scholar
  • 40 Lettieri CJ, Nathan SD, Barnett SD et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746-752
    CrossrefPubMedGoogle Scholar
  • 41 Hoeper MM, Halank M, Wilkens H et al. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur Respir J 2013; 41: 853-860
    CrossrefPubMedGoogle Scholar
  • 42 Guazzi M, Galie N. Pulmonary hypertension in left heart disease. Eur Respir Rev 2012; 21: 338-346
    CrossrefPubMedGoogle Scholar
  • 43 Bonderman D, Ghio S, Felix SB et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 2013; 128: 502-511
    CrossrefPubMedGoogle Scholar
  • 44 Pulido T, Adzerikho I, Channick RN et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809-818
    CrossrefPubMedGoogle Scholar
  • 45 Galie N, Hoeper MM, Humbert M et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263
    CrossrefPubMedGoogle Scholar